

Biomarker-guided clinical trials for rare and very rare cancers

Horizon Europe

Generato il: 8 ottobre 2026

● IN ATTESA

Codice

HORIZON-MISS-2027-02-CANCER-03

Ambito

Internazionale

Località

Europa

Curatore

Marlene Faria

Dettagli Finanziari

Tipo di supporto

Fondo perduto

Tasso Massimo di Finanziamento

100%

Budget

24M€

Valore di Progetto Ammissibile

7M€ - 9M€

Date e Scadenze

Data di Pubblicazione

5 ottobre 2026

Data di Apertura

10 febbraio 2027

Fase unica

16 settembre 2027 alle ore 17:00 GMT+2

Descrizione

Objectives

The main goal of this incentive is to advance biomarker-guided medicines and multi-modal treatment interventions specifically tailored for patients with rare and very rare cancers. The target group includes patients, researchers, physicians, innovators, startups, SMEs, charities, healthcare providers, and policymakers across EU Member States and Associated Countries. The aim is to enable access to early-stage trials, innovative technologies, and validated interventions that have the potential to significantly improve overall survival rates and expand therapeutic options where few exist today.

Funding

Funding is provided under a Horizon Europe Research and Innovation Action (RIA) within the framework of the EU Mission on Cancer. The topic has an indicative budget of €24 million, with the European Commission expecting to fund three projects. The expected EU contribution ranges between €7 million

and €9 million per project, although proposals requesting different amounts may be considered where adequately justified.

Spese Ammissibili

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs
- Preclinical research
- Clinical trial costs
- Networking and meetings
- Stakeholder engagement
- Data management
- Regulatory consultation costs
- Open data infrastructure
- Patient and caregiver involvement activities

Bonus e Maggiorazioni

- Participation in EU Cancer Mission 'Diagnosis and treatment' cluster
- Collaboration with Knowledge Centre on Cancer resources

Idoneità

Settori Idonei

Salute e Life Sciences

Modalità di Candidatura

Aggregata / Partenariato

Tipologie Aziendali

- PMI
- Grande impresa
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Preclinical validation
- Clinical trials
- Innovative medicine validation
- Biomarker-guided drug development

- Patient engagement
- Open science data management
- Stakeholder coordination
- Research and Innovation Actions

Dettagli Programma UE

ID Bando

HORIZON-MISS-2027-02-CANCER-03

Cluster

Mission

Destinazione

Cancer

Modalità di Presentazione

Single-stage

Contributo UE

Around €7,000,000.00 to €9,000,000.00 per project

Progetti Previsti

3

Regola del Tasso di Finanziamento

Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Link Ufficiali

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-03?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-03&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/biomarker-guided-clinical-trials-for-rare-and-very-rare-cancers>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabed>